Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in Menstrual Migraine
NCT06173661Phase 4Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in menstrual migraine comparing Fremanezumab with Placebo (2 arms). Primary endpoint: Migraine Days at 6 months. Started Mar 2024; status: completed.
02
Drugs
fremanezumab
03
Conditions
menstrual migraine
Beyond the preview
Go deeper on NCT06173661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173661.